Sign In
Buy OKYO
$1.66
-0.0400 (-2.35%)
At Close: Jun 03, 2026
OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting
11:30am, Friday, 30'th Jan 2026
LONDON and NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropat
OKYO Pharma to present urcosimod Phase 2 results at ASCRS 2026 annual meeting
07:13am, Friday, 30'th Jan 2026
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company focused on therapies for neuropathic corneal pain (NCP) and inflammatory eye...
OKYO Pharma reports positive FDA feedback on planned neuropathic corneal pain trial
08:45am, Wednesday, 28'th Jan 2026
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has received positive feedback from the US Food and Drug Administration (FDA) following a Type C meeting on the design of its planned Phase 2b/3 clinica
OKYO Pharma Announces Successful Type C Meeting with the FDA
07:40am, Wednesday, 28'th Jan 2026
LONDON and NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropa
OKYO Pharma reports positive FDA feedback on planned neuropathic corneal pain trial
03:43am, Wednesday, 28'th Jan 2026
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has received positive feedback from the US Food and Drug Administration (FDA) following a Type C meeting on...
OKYO Pharma gets FDA nod for compassionate use of eye drug in neuropathic corneal pain
08:43am, Friday, 23'rd Jan 2026
OKYO Pharma Ltd (NASDAQ:OKYO) said on Friday the US Food and Drug Administration has authorized a single-patient expanded access, or compassionate use, investigational new drug application for its exp
FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain
07:00am, Friday, 23'rd Jan 2026
LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropa
Duolingo is more game than classroom, Bank of America says in Buy upgrade
09:32am, Monday, 05'th Jan 2026
Bank of America upgraded Duolingo Inc to Buy on Monday, arguing the market is undervaluing the language-learning app by viewing it too narrowly as an...
OKYO Pharma names ophthalmology veteran Robert Dempsey as CEO
08:42am, Monday, 05'th Jan 2026
OKYO Pharma Ltd (NASDAQ:OKYO) has appointed ophthalmology veteran Robert Dempsey as its new CEO. The NASDAQ-listed, clinical-stage biopharmaceutical company said Dempsey takes on the CEO role with imm
OKYO Pharma management team to ring Nasdaq opening bell
08:49am, Friday, 19'th Dec 2025
OKYO Pharma Ltd (NASDAQ:OKYO) announced that its executive chairman and founder, Gabriele Cerrone, along with members of the company's management team, will ring the Nasdaq Opening Bell at the Nasdaq
Nasdaq charges higher, led by Oracle and Micron
07:56am, Friday, 19'th Dec 2025
12:56pm: More data, more questions Post-shutdown economic data continued to roll in this week, including employment figures for October and November,...
OKYO Pharma to Ring the Opening Bell at Nasdaq
07:00am, Friday, 19'th Dec 2025
LONDON and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (N
OKYO Pharma Announces Chairman and Founder Acquires Shares
08:30am, Monday, 15'th Dec 2025
LONDON and NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corne
Nasdaq tumbles to close out brutal week for tech stocks
11:18am, Friday, 12'th Dec 2025
4:15pm: Rising yields hit tech Stocks limped into the weekend on Friday, with tech once again dragging the major indexes lower as investors rotated out of...
FTSE 100 Live: London stocks pare gains; US futures point to mixed start
08:43am, Friday, 12'th Dec 2025
FTSE down 4 points at 9,699 UK GDP slips 0.1% in October Silver touches a new high US futures point to mixed start 1.42pm: Trump moves to loosen AI red...
